Bone mineral density in angelman syndrome

Area of Science:

• Medical Science
• Genetics
• Pediatrics

Background:

• Angelman syndrome is a rare genetic disorder.
• Patients with Angelman syndrome often experience neurological issues, including epilepsy.
• The impact of Angelman syndrome and its treatments on bone health is not well understood.

Purpose of the Study:

• To assess bone mineral density in patients with Angelman syndrome.
• To compare bone density in Angelman syndrome patients with epileptic and healthy controls.
• To investigate the potential influence of antiepileptic drug therapy on bone health in Angelman syndrome.

Main Methods:

• Dual-energy X-ray absorptiometry (DXA) was used to measure bone mineral density at the lumbar spine (L1-L4).
• Z-scores were evaluated for all patients, and T-scores for those aged 18 years or older.
• Bone mineral density was compared between 18 Angelman syndrome patients, 18 epileptic controls, and 24 healthy controls.

Main Results:

• Abnormal bone mineral density was found in 44.5% of Angelman syndrome patients and 38.9% of epileptic controls, versus none in healthy controls.
• Angelman syndrome patients on antiepileptic drugs, primarily valproic acid, showed significantly lower bone density compared to younger patients or those with shorter treatment durations.
• Osteopenia was identified in nearly half of the pediatric and young adult Angelman syndrome cohort.

Conclusions:

• Angelman syndrome is associated with a high prevalence of osteopenia.
• Long-term treatment with antiepileptic drugs may contribute to reduced bone mineral density in these patients.
• Routine bone mineral densitometry is advised for all Angelman syndrome patients, particularly those undergoing antiepileptic therapy.